Do mutations of the Pendred syndrome gene, SLC26A4, confer resistance to asthma and hypertension?

National Institutes of Health, 5 Research Court, Rockville, Maryland 20850-3320, USA.
Journal of Medical Genetics (Impact Factor: 6.34). 04/2009; 46(6):405-6. DOI: 10.1136/jmg.2008.063610
Source: PubMed


Mutations of SLC26A4 cause Pendred syndrome, an autosomal recessive disorder comprising goitre and deafness with enlarged vestibular aqueducts (EVA). Recent studies in mouse models implicate Slc26a4 in the pathogenesis of asthma and hypertension. We hypothesise that asthma and hypertension are less prevalent among humans with SLC26A4 mutations.
We reviewed medical histories and SLC26A4 genotypes for 80 individuals with EVA and 130 of their unaffected family members enrolled in a study of EVA. We used Fisher's exact test to compare the prevalence of asthma and hypertension among groups of subjects with zero, one, or two mutant alleles of SLC26A4.
Although none of the 21 subjects with two mutant alleles of SLC26A4 had asthma or hypertension, there were no statistically significant differences in the prevalence of asthma or hypertension among subjects with zero, one, or two mutant alleles.
There might be a protective effect of SLC26A4 mutations for asthma and hypertension but our study is statistically underpowered to detect this effect. Study sizes of at least 1125 and 504 individuals will be needed for 80% power to detect an effect at alpha = 0.05 for asthma and hypertension, respectively. Our hypothesis merits a larger study since it has implications for potential strategies to treat hearing loss by manipulating SLC26A4 expression or function.

10 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Inequities in health and health care have increasingly become an area for concern and action for public health professionals, clinicians, policy makers, and communities. Research has documented inequities in the prevalence of chronic diseases of subpopulations defined by education, income, race and ethnicity, and English proficiency. Justice, a cornerstone of medical ethics, calls for corrective actions (1). We contend that all communities contain a minority group whose health needs are understudied and underserved. This group is the sign language-using deaf population. Most sign language users have been deaf since birth or early childhood (2-7). Sign language is not global nor is it based on a local spoken language. For example, British Sign Language (BSL) and American Sign Language (ASL) are distinct languages with little in common with the English language or each other. In the United States, an estimated 100,000 to 1 million people use ASL as their primary language. We describe 4 issues that underlie health inequities experienced by deaf sign language users and propose 6 public health approaches to address these health and health care inequities to promote health and prevent chronic diseases.
    Preventing chronic disease 03/2011; 8(2):A45. · 2.12 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Signaling through the interleukin-4/interleukin-13 (IL-4/IL-13) receptor complex is a crucial mechanism in the development of bronchial asthma and chronic obstructive pulmonary disease (COPD). In bronchial epithelial cells, this signaling pathway leads to changes in the expression levels of several genes that are possibly involved in protection against and/or pathogenesis of these diseases. The expression of pendrin (SLC26A4), a candidate for the latter category, is upregulated by IL-4/IL-13 and leads to overproduction of mucus and increased viscosity of the airway surface liquid (ASL). Therefore, elucidating the transcriptional regulation of pendrin could aid in the development of new pharmacological leads for asthma and/or COPD therapy. Here we show that IL-4/IL-13 significantly increased human pendrin promoter activity in HEK-Blue cells but not in STAT6-deficient HEK293 Phoenix cells; that mutation of the STAT6 binding site (N(4) GAS motif) rendered the promoter insensitive to IL-4/IL-13; and that addition of the N(4) GAS motif to an IL-4/IL-13-unresponsive sequence of the human pendrin promoter conferred sensitivity to both ILs.
    Clinical Pharmacology &#38 Therapeutics 09/2011; 90(3):399-405. DOI:10.1038/clpt.2011.128 · 7.90 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The expression and function of the anion exchanger pendrin (SLC26A4) was thought to be limited mainly to the inner ear, kidney and thyroid. Recent data indicates that pendrin is also expressed in the bronchial epithelium following exposure to the T(H)2-type cytokines, interleukin (IL)-4 and IL-13. Expression of the transporter is also upregulated in bronchial asthma and chronic obstructive pulmonary disease. Both diseases involve respiratory inflammation leading to tissue destruction/remodeling and decreased airway function, and data so far indicate that increased pendrin expression and/or activity might contribute to their pathogenesis. In this review, we summarize data that have emerged within the past years aimed at revealing the role for pendrin in the airway epithelia.
    Cellular Physiology and Biochemistry 11/2011; 28(3):571-8. DOI:10.1159/000335115 · 2.88 Impact Factor
Show more


10 Reads
Available from